Therefore, the potential translation of our findings into clinical practice will present an important advantage: individuals living with diabetes/obesity could be treated with a combination of e.g. GLP-1R/NPY2R agonists for body weight regulation and glucose control, potentially resulting in a highly prophylactic value for the management of stroke sequelae. The gene discussed is GLP1R; the disease is stroke disorder.